Physician profile
Claudia Esson
NPI 1629576301
$312.76
in general payments reported to CMS, 2019-2025
11 companies · $194 in 2025
The $194 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $58.41 · 2024: $60.85 · 2025: $194.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $254.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $254.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Averitas Pharma INC. | $49.08 | 2025 | Qutenza |
| Otsuka America Pharmaceutical, INC. | $42.05 | 2022 | |
| Lilly USA, LLC | $34.26 | 2025 | Mounjaro, Zepbound |
| Nevro Corp. | $33.43 | 2024 | Senza |
| Dexcom, INC. | $30.62 | 2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor |
| Exact Sciences Corporation | $27.42 | 2024 | Cologuard Collection Kit |
| Vertex Pharmaceuticals Incorporated | $23.49 | 2025 | |
| Beta Bionics, INC. | $21.61 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Radius Health, INC. | $19.13 | 2025 | Tymlos |
| Glaxosmithkline, LLC. | $16.36 | 2022 | |
| Merck Sharp & Dohme LLC | $15.31 | 2025 | Pifeltro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Claudia Esson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.